Depression of prahydroxylation of diphenylhydantoin by antituberculosis chemotherapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000627:therapeutic use*; D001259:Ataxia / Q000209:etiology*; D003523:Cycloserine / Q000627:therapeutic use*; D004344:Drug Incompatibility; D004361:Drug Tolerance; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use*; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009759:Nystagmus, Pathologic / Q000209:etiology*; D010672:Phenytoin / Q000009:adverse effects* / Q000378:metabolism* / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*
D000636:Aminosalicylic Acids; D000927:Anticonvulsants; D010672:Phenytoin; D005492:Folic Acid; D003523:Cycloserine; D007538:Isoniazid